

10-2008


Immune Evasion by Rabies Viruses through the Maintenance of Blood-Brain Barrier Integrity.

Anirban Roy
Thomas Jefferson University

Douglas C. Hooper
Thomas Jefferson University, douglas.hooper@jefferson.edu

Let us know how access to this document benefits you

Follow this and additional works at: <http://jdc.jefferson.edu/cbfp>

 Part of the [Amino Acids, Peptides, and Proteins Commons](#), [Biological Phenomena, Cell Phenomena, and Immunity Commons](#), [Medical Immunology Commons](#), [Medical Neurobiology Commons](#), and the [Virus Diseases Commons](#)

Recommended Citation

Roy, Anirban and Hooper, Douglas C., "Immune Evasion by Rabies Viruses through the Maintenance of Blood-Brain Barrier Integrity." (2008). *Department of Cancer Biology Faculty Papers*. Paper 19.
<http://jdc.jefferson.edu/cbfp/19>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Cancer Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Immune Evasion by Rabies Viruses Through the Maintenance of Blood-Brain Barrier Integrity

Anirban Roy and D. Craig Hooper*

Running Title: The BBB prevents rabies virus clearance

Keywords: blood brain barrier, rabies virus, immune evasion, CNS immunity

*Address correspondence to:

D. Craig Hooper, Ph.D.

Center for Neurovirology, Thomas Jefferson University,
1020 Locust St., JAH 454, Philadelphia, PA 19107-6799.

Tel: 215 503-1774, Fax: 215 923-7745

Email: douglas.hooper@jefferson.edu

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

ABSTRACT

The attenuated rabies virus (RV) strain Challenge Virus Standard (CVS)-F3 and a highly pathogenic strain associated with the silver-haired bats (SHBRV) can both be cleared from the central nervous system (CNS) tissues by appropriate anti-viral immune mechanisms if the effectors are provided access across the blood-brain barrier (BBB). In the case of SHBRV infection anti-viral immunity develops normally in the periphery but fails to open the BBB, generally resulting in a lethal outcome. To determine whether or not an absence in the CNS targeted immune response is associated with the infection with other pathogenic RV strains we have assessed the development of immunity, BBB permeability and immune cell infiltration into the CNS tissues of mice infected with a variety of RV strains including the dog variants responsible for the majority of human rabies cases. We demonstrate that the lethal outcomes of infection with a variety of known pathogenic RV strains are indeed associated with the inability to deliver immune effectors across the BBB. Survival from infection with certain of these viruses is improved in mice prone to CNS inflammation. The results suggest that competition between the activity of the immune effectors reaching CNS tissues and the inherent pathological attributes of the virus dictates the outcome and that intervention to deliver RV-specific immune effectors into CNS tissues may have general therapeutic value in rabies.

45 **INTRODUCTION**

46 Rabies has been known for centuries as a deadly neurological disease of both humans
47 and animals. The causative agent belongs to a group of antigenically related viruses named
48 after the disease, the rabies viruses (RV). RV strains varying in their genotypes and
49 pathogenicity can be found associated with diverse reservoir species in different geographic
50 locations (Kissi et al., 1995). Each RV strain is associated with a particular natural host
51 species, usually canines and other small carnivores, such as raccoons and skunks as well as
52 bats (Baer et al., 1990). RV strains associated with dogs are the major cause of human rabies
53 worldwide due to prevalence of the virus in developing countries, while an RV strain
54 associated with silver-haired bat (SHBRV) is responsible for most of the endogenous human
55 rabies cases in the United States and Canada (Messenger et al., 2003).

56 While rabies is generally fatal once the early clinical signs of the disease appear,
57 prompt treatment measures that include wound cleansing and passive administration of RV-
58 neutralizing antibodies together with active immunization can prevent development of the
59 disease in an individual exposed to the virus (Fu, 1997). This approach, called post-exposure
60 prophylaxis (PEP), fails to protect an infected individual once neurological signs are apparent
61 (CDC MMWR, 1999). Since neurological signs are indicative of virus replication in the
62 central nervous system (CNS) tissues, it is generally considered to be impossible to clear the
63 virus and save a RV infected individual once RV has spread to the brain from its peripheral
64 site of entry. However, this is not always the case. In a well-documented recent example, a
65 rabies patient who developed evidence of antiviral immunity recovered despite developing
66 severe neurological signs (Willoughby et al., 2005). There is also historical evidence of
67 individuals surviving likely infections with the virus (Gremliza, 1953; Hattwick et al, 1972) as

68 well as laboratory evidence that RV can be cleared from the CNS tissues if appropriate
69 immune mechanisms develop (Jackson et al., 1989). We have recently elucidated several of
70 the processes required to clear the attenuated RV strain Challenge Virus Standard (CVS)-F3
71 from the CNS (Phares et al., 2006). These include the development of an innate immune
72 response in the CNS tissues and adaptive RV-specific immunity in the peripheral lymphoid
73 organs as well as the infiltration of immune effectors across the blood-brain barrier (BBB)
74 (Phares et al., 2006). The latter is associated with increased BBB permeability to fluid phase
75 markers primarily in the cerebellum of the infected mice (Phares et al., 2006). We have
76 determined that the BBB remains intact and immune cells do not enter the CNS tissues in
77 animals infected with SHBRV (Roy et al., 2007). Consequently, the virus is not cleared and
78 SHBRV-infected animals die of rabies (Roy et al., 2007). Increasing BBB permeability in
79 SHBRV infected animals through the induction of an autoimmune CNS inflammatory
80 response facilitates immune cell entry into the infected CNS tissues and promotes virus
81 clearance thereby preventing the lethal outcome of the infection (Roy and Hooper, 2007).
82 White blood cells and virus specific antibodies was also found to accumulate in the CSF in a
83 patient who survived clinical rabies (Willoughby et al., 2005).

84 Unlike classical rabies, which results from the bite of an infected dog an incident
85 causing infection with SHBRV often goes unnoticed (Jackson and Fenton, 2001; CDC
86 MMWR, 1999, 2007), leading to speculation that these variants may have unique attributes,
87 possibly including the capacity to evade immune clearance. Alternatively, all pathogenic RV
88 strains may interfere with antiviral immune mechanisms at some stage of the infection, an
89 attribute that would explain the failure of PEP later in the disease. To distinguish between

90 these alternatives we have assessed BBB function and immune cell invasion into the CNS
91 tissues of mice infected with a variety of RV strains.

92 **MATERIALS AND METHODS**

93 *Animals and virus.*

94 129/SvEv mice were obtained from the in-house breeding colony at Thomas Jefferson
95 University and PLSJLF1/J (PLSJL) mice were purchased from Jackson Laboratories (Bar
96 harbor, ME). Eight to 10 -week old mice ($n \geq 10$ per group) were infected via intra-dermal
97 (ID) route in the ear as previously described (Roy et al., 2007). The inoculation dose used and
98 a brief description of each RV strain studied are presented in Table 1. The doses for the
99 pathogenic RV strains were approximately $10 \times LD_{50}$ (ID) in mouse. Cell culture adapted
100 strains that are not lethal for immunocompetent animals were administered at 10^5 focus
101 forming units, an amount that is known to cause CNS infection for CVS-F3 (Phares et al.,
102 2006). All procedures were carried out according to the protocols approved by the
103 Institutional Animal Care and Use Committee of Thomas Jefferson University.

104

105 *Tissue collection.*

106 Mice were anesthetized and the thoracic cavity was surgically opened. Cardiac blood
107 was collected and mice were transcardially perfused with 15 mL of PBS supplemented with
108 1U/mL Heparin followed by 15 mL of PBS. Brains were collected and the cerebral cortex and
109 the cerebellum were separated. Tissues were snap frozen in liquid nitrogen and stored at –
110 80°C until further use.

111

112 *RT-PCR.*

113 As an indicator of virus replication, RV nucleoprotein-specific mRNA levels were
114 measured in the CNS tissues from infected mice by the reverse transcriptase–polymerase

115 chain reaction (RT-PCR) technique. Briefly, total RNA was isolated from the snap frozen
116 brain tissues of RV-infected and uninfected control mice using the Qiagen RNeasy Kit
117 (Valencia, CA) as previously described (Phares et al., 2006). cDNAs were synthesized from
118 mRNA by reverse transcription using oligo (dT) as primer. Approximately 100 ng of cDNA
119 was subjected to PCR amplification using primers specific for a segment of nucleoprotein
120 gene that is largely conserved among all of the virus strains used in the current study. The
121 gene for the house-keeping ribosomal protein L-13 was quantified in each sample to ensure
122 that the quantities of cDNA used for PCR are almost equal in all samples. The nucleotide
123 sequences of the primers used for PCR are: forward primer for RV nucleoprotein gene, 5'-TA
124 CAATGGATGCCGACAAGA -3'; reverse primer for RV nucleoprotein gene, 5'-AAAGGG
125 GCTGTCTCGAAAAT-3'; forward primer for L-13, 5'-TTCCACAAGGATTGGCAGCA-3';
126 and reverse primer for L-13, 5'-TGCTCGGATTGCCAAAGAGT-3'. Equal amounts of the
127 PCR products were subjected to gel electrophoresis using 1% agarose gel and bands of
128 amplified DNA were visualized under UV light and photographed using a gel-documentation
129 system (Bio-Rad).

130

131 ***Quantitative Real Time-PCR***

132 The levels of mRNAs specific for TNF- α , IL-6, CD4, CD19 and κ -light chain genes
133 were measured in cDNA samples by quantitative real-time PCR (QRT-PCR) as previously
134 described, using TaqMan PCR reagents (Applied Biosystems, Foster City, CA), gene-specific
135 primers and probes, synthetic gene standards, and a Bio-Rad iCycler iQ Real Time Detection
136 System (Hercules, CA) (Phares et al., 2006). In each sample, the mRNA copy numbers of a
137 particular gene were normalized to the mRNA copy number of the housekeeping gene L13.

138 Levels of gene expression in a test sample are presented as the fold increase over that detected
139 in uninfected controls using the formula: n-fold increase = [mRNA copy numbers of a
140 particular gene in a RV-infected sample/ mRNA copy numbers of L13 in that sample] /
141 average of [mRNA copy numbers of that particular gene in an uninfected mouse sample /
142 mRNA copy numbers of L13 in that sample]. The sequences of the primers and probes used
143 for quantitative PCR have been previously detailed (Phares et al., 2006).

144

145 ***Measurement of serum antibody titers.***

146 Levels of RV-specific total immunoglobulin-gamma (IgG) in sera from uninfected and
147 RV-infected mice were measured by Enzyme Linked Immunosorbent Assay (ELISA) as
148 described previously (Roy et al., 2007). Briefly, serially diluted sera samples were incubated
149 at room temperature in 96-well plates (Nalge Nunc International, Rochester, NY) coated with
150 UV-inactivated Evelyn-Rokitnicki-Abelseth (ERA) or CVS-F3 (5µg/ml). Captured antibodies
151 were detected using peroxidase-conjugated anti-mouse IgG (Sigma). 3, 3', 5, 5' –
152 Tetramethylbenzidine dihydrochloride substrate (Sigma) supplemented with hydrogen
153 peroxide was used for color development. The reaction was terminated by the addition of 2M-
154 H₂SO₄ to the wells and the absorbance was measured at 450 nm in a microplate
155 spectrophotometer (Biotek, Winooski, VT). Antibody titer is calculated as the inverse of the
156 dilution of a serum sample corresponding to the half of the maximum absorbance detected in
157 that sample.

158

159 ***Assessment of BBB permeability.***

160 The extent of BBB permeability was assessed by measuring the amount of a low
161 molecular weight fluorescent marker (Na-fluorescein, molecular weight 376) that leaks from

162 the circulation into the CNS tissues as previously described (Phares et al., 2006). Briefly,
163 100µl of 10% solution of Na-fluorescein was injected intra-peritoneally and after 10 minutes
164 mice were anesthetized and transcardially perfused as described above. Snap frozen brains
165 were homogenized in phosphate buffered saline (PBS) and centrifuged. Proteins from the
166 supernatants of the tissue homogenate as well as from serum samples were precipitated with
167 15% TCA. Fluorescence in the clarified supernatant was measured at excitation and emission
168 wavelengths of 485nm and 530nm respectively, using a CytoFluor™ II fluorimeter (PerSeptive
169 Biosystems, Framingham, MA). The amount of Na-fluorescein in the CNS tissue of each
170 animal was normalized to the level of Na-fluorescein detected in the animal's serum using the
171 formula: Na-fluorescein uptake = [amount of Na-fluorescein detected in the CNS tissue of a
172 mouse/ weight of the tissue]/ amount of Na-fluorescein detected per µL of serum of that
173 mouse. Na-fluorescein uptake into the tissues of each infected animal was divided by the
174 average uptake detected in similar tissues from uninfected control mice and the results are
175 expressed as fold increase.

176

177 ***Statistical analyses.***

178 Results are expressed as the mean ± the standard error of the mean. The statistical
179 significance of the differences in gene expression and in serum antibody levels between
180 control and infected groups was assessed using the Mann-Whitney test while the *t*-test was
181 used to test the significance of differences in virus nucleoprotein mRNA levels.

182 **RESULTS**

183

184 *The outcomes of infection with different RV strains differ.*

185 Ten different RV strains ERA, PM, CVS-F3, DRV-4, Thai-DRV, CVS-N2c, CosRV,
186 SkunkRV, SHBRV and HEP were used in the current study (see Table 1). Groups of
187 129/SvEv mice were infected via the ID route with each of the RV strains and 8 days
188 following infection, RT-PCR was used to detect the presence of viral nucleoprotein mRNA in
189 the CNS tissues. Viral nucleoprotein message was found in the cortices and the cerebella of
190 all infected mice, with the exception of those that had received the HEP strain (Fig 1). We
191 were unable to detect nucleoprotein message for HEP by RT-PCR in any part of the CNS
192 tissues (olfactory bulbs, cerebral cortex, cerebellum, brain stem and spinal cord) following
193 either ID or intra-nasal administration of HEP (data not shown). However, HEP nucleoprotein
194 mRNA can be detected in cell culture by RT-PCR using the same set of RV specific primers
195 used in this study.

196 Similar groups of infected 129/SvEv mice were monitored for mortality. Mice infected
197 with Thai-DRV, CVS-N2c and SHBRV died around 8-12 days postinfection whereas mice
198 infected with DRV-4, CosRV and SkunkRV died within 12-17 days after infection (Fig 2).
199 Despite the fact that the relatively less pathogenic RV strains, namely ERA, PM and CVS-F3,
200 reached the CNS, mice infected with these strains of RV survived the infection (Fig 2). Mice
201 receiving the HEP RV strain survived without any sign of disease over a 30-day observation
202 period.

203

204

205 ***Innate immunity is induced in the CNS by all neuroinvasive RV strains.***

206 When RV reaches the CNS tissues it induces the expression of pro-inflammatory
207 cytokines of the innate immune response (Phares et al., 2006; Marquette et al., 1996). A
208 difference in the capacity of different RV strains to induce a CNS innate immunity has been
209 suggested to be associated with the pathogenicity of that virus (Wang et al., 2005). Infection
210 with all of the RV strains that reached the CNS of the 129/SvEv mice upregulates the
211 expression of genes specific for the pro-inflammatory cytokines TNF- α and IL-6 (Fig 3).
212 Moreover, the expression of these genes is elevated to more or less equivalent extents
213 irrespective of the pathogenicity of the RV strain. Enhanced TNF- α and IL-6 expression was
214 not seen in the CNS of mice receiving HEP RV, providing support for the likelihood that this
215 particular RV strain is not neuroinvasive.

216

217

218 ***All RV infections induce strong RV-antigen specific antibody response.***

219 As shown in Fig 4, regardless of the pathogenicity of the infecting virus, all RV
220 infected animals including those receiving HEP, developed an RV-specific IgG response. The
221 serum antibody titers raised by infection with the different viruses were approximately the
222 same with the exception of mice infected with the ERA strain where substantially higher
223 serum antibody titers were seen. Notably, although no evidence of either virus replication or
224 induction of pro-inflammatory genes in the CNS of HEP infected mice was detected, serum
225 RV-specific antibody titers in these mice were equivalent to those of mice infected with other
226 RV strains.

227

228 *Virus is cleared and animals survive only where anti-RV adaptive immune effectors reach*
229 *the CNS.*

230 Clearance of RV from the CNS requires the invasion of the CNS tissues by immune
231 cells, a process that primarily occurs in the cerebellum and, for CVS-F3, involves the activity
232 of CD4 T-cells and B cells (Phares et al., 2006 and 2007). In the absence of the accumulation
233 of these immune effectors in CNS tissues, RV infection is lethal (Roy et al., 2007). Eight days
234 following infection, the expression of the mRNAs specific for CD4, CD19 (phenotypic
235 markers for T- and B-cells, respectively) and κ -light chain (an indicator of antibody
236 production by B-cells) is greatly elevated in the cerebella of mice infected with the less
237 pathogenic ERA, PM and CVS-F3 strains of RV (Fig 5). On the other hand, no significant
238 increase in the expression levels of these genes is seen in the cerebella of mice infected with
239 the pathogenic RV strains DRV-4, Thai-DRV, CVS-N2c, CosRV, SHBRV and SkunkRV
240 (Fig 5).

241 As immune-cell infiltration into the CNS tissues of CVS-F3 infected mice is
242 accompanied by an increase in BBB permeability to the fluid phase marker Na-fluorescein,
243 we next assessed BBB integrity during infection with the different RV strains. The results
244 paralleled the difference in immune cell invasion of CNS tissues between less pathogenic and
245 pathogenic strains of RV. BBB permeability in the cerebellum was indeed significantly
246 enhanced in animals infected with ERA, PM and CVS-F3 strains, but not in animals infected
247 with DRV-4, Thai-DRV, CVS-N2c, CosRV, SHBRV and SkunkRV strains (Fig 6).

248

249

250

251 *PLSJL mice are more resistant to the death from infection with different pathogenic RV*
252 *strains.*

253 We have previously shown that PLSJL mice are somewhat more resistant to lethal
254 infection with SHBRV than 129/SvEv mice (Roy and Hooper, 2007). To test if PLSJL mice
255 are less susceptible to lethal infection with other pathogenic RV strains, groups of 129/SvEv
256 and PLSJL mice were infected with different RV strains and monitored for clinical signs of
257 rabies and mortality for a period of 30 days post infection. Between 8 to 15 days after
258 infection, 129/SvEv mice infected with all RV strains, except HEP, showed prominent
259 neurological signs of rabies (Table 2). Those infected with the pathogenic DRV-4, Thai-DRV,
260 CVS-N2c, CosRV, SHBRV and SkunkRV strains died within 2-5 days of the appearance of
261 clinical signs, whereas 129/SvEv mice infected with the less pathogenic ERA, PM and CVS-
262 F3 strains survived. ERA infected 129/SvEv mice had persistent neurological signs for over
263 10-15 days after first appearance, but nevertheless survived the infection. On the other hand,
264 almost all of the PLSJL mice infected with ERA, PM and CVS-F3 as well as DRV-4, CosRV
265 and SkunkRV survived the infection without any sign of disease (Table 2). Only one mouse in
266 each of the CosRV and Skunk RV infected groups developed neurological signs and both died
267 of rabies. However, the majority of Thai-DRV, CVS-N2c and SHBRV infected PLSJL mice
268 died of rabies after developing neurological signs similar to those appearing in 129/SvEv mice
269 infected with the same RV strains. The PLSJL mice that survived infection with these viruses
270 did not develop any signs of clinical rabies (Table 2). As an initial probe into why PLSJL
271 mice may survive infections with RV strains that are lethal for 129/SvEv mice we used
272 quantitative RT-PCR to assess the amounts of virus nucleoprotein message in the CNS of
273 mice infected with two RV strains, CosRV, which is pathogenic in 129/SvEv mice but non-

274 pathogenic in PLSJL mice, and CVS-N2c, which is pathogenic in both 129/SvEv and PLSJL
275 mice. At 8 days of infection, the levels of nucleoprotein mRNA of the more pathogenic CVS-
276 N2c strain were several thousands fold higher in the CNS of both 129/SvEv and PLSJL mice
277 than those of the CosRV strain (Fig 7). However, the nucleoprotein mRNA levels of both
278 viruses were significantly lower in PLSJL mice (Fig 7). Significantly, the only group of mice
279 that survive, PLSJL mice infected with CosRV, exhibits the lowest viral nucleoprotein mRNA
280 levels.

281

282

283

284 **DISCUSSION**

285 We have previously shown that while RV-specific immunity develops in the periphery
286 of mice infected with either the attenuated variant CVS-F3 or the highly pathogenic SHBRV,
287 immune effectors are not delivered across the BBB into the CNS tissues of the latter (Roy et
288 al., 2007). These findings led us to speculate that the mechanisms providing RV-specific
289 immune effectors access to CNS tissues fail during infection with SHBRV and possibly other
290 neurotropic viruses (Roy et al., 2007). In this study we have tested the hypothesis with respect
291 to pathogenic RV by comparing the development of peripheral and CNS immunity in mice
292 infected with a variety of RV strains that differ in pathogenicity. The data clearly show that a
293 reduction in the capacity to deliver immune effectors across the BBB into CNS tissues is
294 common to infection with different pathogenic RV isolates. In our survey of infection with
295 diverse RV variants we identified only a single strain, HEP, that does not appear to spread to
296 the CNS of 129/SvEv mice. We failed to detect viral message or evidence of innate immunity
297 to the virus in CNS tissues from mice infected with HEP, which is considered to be poorly
298 neuroinvasive due to the presence of glutamine at position 333 in its glycoprotein
299 (Dietzschold et al, 1983; Takayama-Ito et al., 2006). Nevertheless, the administration of HEP
300 stimulated a strong RV-specific antibody response. In contrast, all of the other RV strains
301 tested were neuroinvasive as nucleoprotein mRNAs were detectable in the CNS tissues, as
302 were elevations in markers of innate immunity. DRV-4, Thai-DRV, CVS-N2c, CosRV and
303 Skunk RV were lethal for 129/SvEv mice, while similar mice infected with CVS-F3, ERA
304 and PM strains survived. Unlike CVS-F3-infected mice where neurological disease was not
305 seen prior to recovery, 129/SvEv mice infected with ERA and PM exhibited overt
306 neurological signs resembling those of mice lethally infected with DRV-4. On the basis of

307 these observations we can classify RV into three broad groups: 1/ attenuated viruses that are
308 poorly neuroinvasive (HEP) and a CNS-targeted immune response and changes in BBB
309 permeability are not required for clearance; 2/ attenuated neuroinvasive viruses that reach the
310 CNS (ERA, PM, CVS-F3) but are cleared by immune effectors that cross the BBB; and 3/
311 neuroinvasive, lethal RV where there is no evidence of BBB permeability changes and
312 negligible invasion of immune effectors into CNS tissues (DRV-4, SHBRV, Thai-DRV,
313 CVS-N2c, CosRV, Skunk RV).

314 Adoptive transfer of lymphocytes from 129/SvEv mice lethally infected with SHBRV
315 can clear CVS-F3 from immunodeficient recipients while neither these cells nor similar cells
316 from CVS-F3 - infected donors can clear SHBRV (Roy et al., 2007). We have interpreted
317 these experiments as indicating that some aspect of the SHBRV infection restricts immune
318 effectors from invading CNS tissues (Roy et al., 2007). PLSJL mice, which exhibit a stronger
319 CNS inflammatory response, were found to have an elevated capacity to clear SHBRV (Roy
320 and Hooper, 2007). To provide additional insight into whether or not some aspect of the host
321 response is likely to be a contributing factor in RV infection we compared the outcome of
322 infection with various RV strains in PLSJL and 129/SvEv mice. As previously shown for
323 SHBRV (Roy and Hooper, 2007), DRV-4, CosRV and Skunk RV proved to be less
324 pathogenic in PLSJL mice. In contrast, CVS-N2c and Thai-DRV are highly lethal for both
325 PLSJL and 129/SvEv mice. The capacity of the virus to replicate and spread likely contributes
326 to the outcome. At 8 days post infection high levels of CVS-N2c nucleoprotein mRNAs are
327 present in the CNS of both infected 129/SvEv and PLSJL mice but only moderate levels of
328 CosRV nucleoprotein mRNA in the lethally infected 129/SvEv CNS. These are somewhat
329 reduced in the CNS of PLSJL mice that clear the infection, possibly as a consequence of the

330 initiation of immune-mediated virus clearance. Taken together these results indicate that both
331 host and viral attributes contribute to the lethality of RV infection. In the absence of an
332 effective CNS immune response RV infection is invariably lethal, as is the case for both CVS-
333 N2c and CosRV in 129/SvEv mice. On the other hand, PLSJL mice can survive infection with
334 CosRV but not with the more rapidly replicating CVS-N2c. Conceivably, enhancing the
335 extent of CNS inflammation may have utility in the treatment of RV such as CVS-N2c or
336 Thai-DRV, as has been shown for SHBRV (Roy and Hooper, 2007), but we expect that there
337 is level of infection at which an immune response would no longer be therapeutic.

338 Human rabies is almost always lethal when neurological signs are apparent in the
339 infected host. Since neurological signs are indicative of virus replication inside the CNS
340 tissues, it has generally been considered that once RV has reached the brain it is impossible to
341 clear the virus and the only hope that an individual has of surviving a RV infection is to
342 prevent spread of the virus to the CNS. Thus people who have suffered a probable exposure to
343 a RV are treated by passive administration of pre-formed (exogenous) RV-neutralizing
344 antibodies and by boosting the development of their own (endogenous) RV-specific immunity
345 by vaccination. These treatments, together known as PEP, are thought to act by preventing the
346 spread of RV to the CNS, as they are largely ineffective when given to people who have
347 already manifested neurological signs of rabies (CDC MMWR, 1999). However, this is not
348 always the case. In 2004 a patient survived clinical rabies despite developing neurological
349 signs evidently through the natural development of RV-specific immunity (Willoughby et al.,
350 2005). The appearance of white blood cells, virus specific antibodies and other serum proteins
351 in the cerebrospinal fluid of this individual indicated that the BBB had been breached and that
352 immune effectors likely had access to infected CNS tissues (Willoughby et al., 2005). Our

353 data comparing 129/SvEv and PLSJL mice suggest that host factors, in particular the capacity
354 to deliver immune effectors across the BBB, play a large role in the ability to survive RV
355 infection. This concept is supported by studies of rabies patients where significant serum RV-
356 specific antibody titers are often present (Kasempimolporn et al., 1991), but immune-
357 mediated changes in the CNS tissues are rare (Murphy, 1977).

358 Human rabies associated with dog and other small carnivores is still a major public
359 health problem in most parts of the world, dog rabies alone killing an estimated 50,000 –
360 60,000 people annually (Dressen, 1997; Jackson, 2005). In the United States, around 30,000
361 people receive anti-rabies treatment after being exposed to potentially rabid raccoons and
362 skunks (CDC MMWR, 1999). While there is little objective proof, PEP is generally
363 considered to be effective unless its administration is delayed, as is often the case for lethal
364 infections with SHBRV where exposure to the virus may not be obvious (Messenger et al.,
365 2002). Proper administration of PEP has been known to fail to protect individuals bitten by
366 rabid dogs on the face or other areas that are highly innervated, such as the fingertips (Wilde,
367 2007). In such cases the virus may have reached peripheral nerves quickly after the exposure
368 (Wilde, 2007). Our data would suggest that at some time after the virus has reached the CNS
369 neither PEP nor natural RV-specific immunity can protect an individual because immune
370 effectors are unable to enter the infected CNS tissues. However, we expect that there is a
371 window of time where immune mechanisms can clear RV from the CNS before the infection
372 shuts down the ability to deliver immune effectors into the CNS tissues. In the current study,
373 we found that the RV strains ERA and PM can be cleared from the brain after development of
374 prominent neurological signs of rabies. Our RT-PCR analysis of the CNS tissues confirmed
375 extensive virus replication in the brain during infection with these RV strains. This suggests

376 that rabies is not invariably lethal if the virus can be cleared before neural damage, either
377 caused by the virus or immunopathology, becomes too extensive. Thus, the predominant
378 direct pathogenic attributes of a RV are likely related to its capacity to replicate and spread
379 through CNS tissues (Dietzschold et al., 1985) as well as alter neuronal structure and function
380 (Scott et al., 2008). We expect that these are in turn dependent upon the loss of the ability to
381 support immune cell invasion across the BBB and limit virus spread. The caveat here is that
382 the early development of CNS immunity is likely to be protective while the late development
383 may be detrimental due to immunopathology consequential to more extensive virus spread.
384 Notably, clear evidence of immunopathology was not seen with any of the RV studied here
385 with the possible exception of ERA where an exaggerated immune response was evident in
386 129/SvEv mice and one out of 15 animals died while the rest survived with neurological
387 abnormalities.

388 The concept that there is generally an inverse relationship between the pathogenicity
389 of a RV and the capacity of the host to mediate an RV-specific CNS immune response is
390 supported by the fact that there is little evidence of immune cell infiltration into the infected
391 brain tissues of most individuals that succumb to rabies (Murphy, 1977). In a few human
392 rabies cases CNS inflammation has been reported where immunopathology may have
393 contributed to the death (Suja et al., 2004). While this has not been examined in humans, all
394 of the RV strains studied in animal models induce strong innate, pro-inflammatory responses
395 in the CNS as they reach these tissues (Marquette et al., 1996; Wang et al., 2006; Phares et al.,
396 2006; Fig. 3). Moreover, all RV are evidently highly immunogenic with infection inducing
397 RV-specific antibodies in the sera of infected mice (Smith et al., 1982; Wiktor et al., 1977) as
398 well as humans (Kasempimolporn et al., 1991). In addition, RV can evidently be cleared by

399 immune mechanisms without the immunopathology associated with CNS immune responses
400 to many neurotropic viruses (Miller et al., 1990; Morimoto et al., 1996). Taken together these
401 observations suggest that circumventing the inability of immune effectors to cross the BBB
402 may have therapeutic benefits in people who have developed early signs of rabies. We have
403 previously shown in mouse models that enhancing BBB permeability by the induction of
404 autoimmune CNS inflammation can lead to the clearance of pathogenic RV strains from the
405 brain via naturally developed anti-viral immunity. PLSJL mice, possibly due to an elevated
406 capacity to mediate CNS inflammation, are less likely to die from rabies (Roy and Hooper,
407 2007). These observations not only provide insight into how a rational treatment for rabies
408 may be developed but also how conventional PEP may actually work. It has been well
409 established that passive administration of rabies immunoglobulins (RIG) without active
410 immunization fails to protect RV-infected experimental animals (Hanlon et al., 2002). We
411 speculate that active immunization accelerates the development of RV-specific adaptive
412 immune cells capable of providing immune effectors access to infected neural tissues, a CD4
413 T cell-dependent process (Phares et al., 2007), prior to the loss of the capacity to mediate this
414 process at the BBB. Tailoring a next generation vaccine to target a mechanism that induces
415 functional changes in BBB integrity in a manner that is not susceptible to inhibition may
416 provide a means to survive rabies; if immunopathology can be limited and virus-mediated
417 neuropathology is not extensive or can be reversed.

418

419

420

421

422

423 **ACKNOWLEDGEMENTS**

424 We thank Dr. Charles E. Rupprecht and his colleagues at the Center for Disease
425 Control and Prevention, Atlanta, GA and Dr. Bernard Dietzschold of Thomas Jefferson
426 University, Philadelphia, PA for the provision of the virus strains used in this study. We also
427 thank Rhonda B. Kean and Fatu Badiane for helpful contribution to this work. This work was
428 supported by National Institute of Health Grant AI 077033 and AI 060005.

429

430 **REFERENCES**

- 431 Abelseth, MK (1964). An attenuated rabies vaccine for domestic animals produced in tissue
432 culture. *Can Vet J*, 5, 279-286.
- 433 Baer, GM, Bellini, WJ, Fishbein, DB (1990). Rhabdoviruses. B.N. Fields(ed). pp 883-930.
434 Virology 2nd edition. Raven Press: New York.
- 435 Centers for Disease Control and Prevention (1999). Human rabies prevention - United States.
436 Recommendations of the Advisory Committee on immunization practice. *MMWR*
437 Morb Mortal Wkly Rep, 48, 1-21.
- 438 Centers for Disease Control and Prevention (2007). Human rabies – Indiana and California,
439 2006. *MMWR Morb Mortal Wkly Rep*, 56, 361-365.
- 440 Dietzschold, B, Morimoto, K, Hooper, DC, Smith, JS, Rupprecht, CE, Koprowski, H (2000).
441 Genotypic and phenotypic diversity of rabies virus variants involved in human rabies:
442 implications for postexposure prophylaxis. *J Hum Virol*, 3, 50-57.
- 443 Dietzschold, B, Wiktor, TJ, Trojanowski, JQ, Macfarlan, RI, Wunner, WH, Torres-Anjel, MJ,
444 Koprowski, H (1985). Differences in cell-to-cell spread of pathogenic and apathogenic
445 rabies virus in vivo and in vitro. *J Virol*, 56, 12-8.
- 446 Dietzschold, B, Wunner, WH, Wiktor, TJ, Lopes, AD, Lafon, M, Smith, CL, Koprowski, H
447 (1983). Characterization of an antigenic determinant of the glycoprotein that correlates
448 with pathogenicity of rabies virus. *Proc Natl Acad Sci USA*, 80, 70-4.
- 449 Dressen DW (1997). A global review of rabies vaccine for human use. *Vaccine*, 15, s2-s6.
- 450 Fu, ZF (1997). Rabies and rabies research: past present and future. *Vaccine*, 15, s20-s24.
- 451 Gremliza, L. 1953. Casuistic to the rabies problem. *Z Tropenmed Parasitol*, 4: 382-389.

452 Hanlon, CA, Niezgoda, M, Rupprecht, CE (2002). Post exposure prophylaxis for prevention
453 of rabies in dogs. *Am J Vet Res*, 63(8), 1096-1100.

454 Hattwick, MAW, Weiss, TT, Stechschulte, CJ, Baer, GM, Gregg, MB (1972). Recovery from
455 rabies: a case report. *Ann Intern Med*, 76: 931-942.

456 Jackson, AC (2005). Recovery from rabies. *N Engl J Med*, 352, 2549-2550.

457 Jackson, AC, Fenton, MB (2001). Human rabies and bat bites. *The Lancet*, 357: 1714.

458 Jackson, AC, Reimer, DL, Ludwin. SK (1989). Spontaneous recovery from the
459 encephalomyelitis in mice caused by street rabies virus. *Neuropathol Appl Neurobiol*,
460 15, 459-475.

461 Kasempimolporn, S, Hemachudha, T, Khawplod, P, Manatsathit, S (1991). Human immune
462 response to rabies nucleocapsid and glycoprotein antigens. *Clin Exp Immunol*, 84(2),
463 195-199.

464 Kissi B, Tordo, N, Bourhy, H (1995). Genetic Polymorphism in the Rabies Virus Nucleo-
465 protein Gene. *Virology*, 209, 526-537.

466 Marquette, C, Van Dam, AM, Ceccaldi, PE, Weber, P, Haour, F, Tsiang, H (1996). Induction
467 of immunoreactive interleukin-1 beta and tumor necrosis factor-alpha in the brains of
468 rabies virus infected rats. *J Neuroimmunol*, 68, 45-51.

469 Messenger, SL, Smith, JS, Orciari, LA, Yager, PA, Rupprecht, CE (2003). Emerging pattern
470 of rabies deaths and increased viral infectivity. *Emerg Infect Dis*, 9, 151-4.

471 Messenger, SL, Smith, JS, Rupprecht, CE (2002). Emerging epidemiology of bat-associated
472 cryptic cases of rabies in humans in the United States. *Clin Infect Dis*, 35, 738-47.

473 Miller, SD, Gerety, SJ, Kennedy, MK, Peterson, JD, Trotter, JL, Tuohy, VK, Waltenbaugh, C,
474 Dal Canto, MC, Lipton, HL (1990). Class II-restricted T cell responses in Theiler's

475 murine encephalomyelitis virus (TMEV)-induced demyelinating disease. III. Failure
476 of neuroantigen-specific immune tolerance to affect the clinical course of
477 demyelination. *J Neuroimmuno*, 26, 9-23.

478 Morimoto, K, Hooper, DC, Bornhorst, A, Corisdeo, S, Bette, M, Fu, ZF, Schäfer, MK,
479 Koprowski, H, Weihe, E, Dietzschold, B (1996). Intrinsic responses to Borna disease
480 virus infection of the central nervous system. *Proc Natl Acad Sci USA*, 93, 13345-50.

481 Morimoto, K, Hooper, DC, Spitsin, S, Koprowski, H, Dietzschold, B (1999). Pathogenicity of
482 different rabies virus variants inversely correlates with apoptosis and rabies virus
483 glycoprotein expression in infected primary neuron cultures. *J Virol*, 73, 510-8.

484 Murphy, FA (1977). Rabies pathogenesis. *Arch Virol*, 54, 279-297.

485 Phares, TW, Fabis, MJ, Brimer, CM, Kean, RB, Hooper, DC (2007). A peroxynitrite-
486 dependent pathway is responsible for blood-brain barrier permeability changes during
487 a CNS inflammatory response; TNF- α is neither necessary nor sufficient. *J Immunol*,
488 178, 7334-43.

489 Phares, TW, Kean, RB, Mikheeva, T, Hooper, DC (2006). Regional differences in blood-
490 brain barrier permeability changes and inflammation in the apathogenic clearance of
491 virus from the central nervous system. *J Immunol*, 176, 7666-75.

492 Roy, A, Hooper, DC (2007). Lethal silver-haired bat rabies virus infection can be prevented
493 by opening the blood-brain barrier. *J Virol*, 81(15), 7993-7998.

494 Roy, A, Phares, TW, Koprowski, H, Hooper, DC (2007). Failure to open the blood-brain
495 barrier and deliver immune effectors to the CNS tissues leads to the lethal outcome of
496 Silver-haired bat rabies virus infection. *J Virol*, 81(3), 1110-1118.

497 Rupprecht, CE, Dietzschold, B, Campbell, JB, Charlton, KM, Koprowski, H (1992).
498 Consideration of inactivated rabies vaccines as oral immunogens of wild carnivores. J
499 Wildl Dis, 28(4), 629-35.

500 Rupprecht, CE, Glickman, LT, Spencer, PA, Wiktor, TJ (1987). Epidemiology of rabies virus
501 variants. Differentiation using monoclonal antibodies and discriminant analysis. Am J
502 Epidemiol, 126(2), 298-309.

503 Scott, CA, Rossiter, JP, Andrew, RD, Jackson, AC (2008). Structural abnormalities in
504 neurons are sufficient to explain the clinical disease and fatal outcome in experimental
505 rabies in yellow fluorescent protein-expressing transgenic mice. J Virol, 82(1), 513-
506 21.

507 Smith, JS, McClelland, CL, Reid, FL, Baer, GM (1982). Dual role of the immune response in
508 street rabies virus infection of mice. Infect Immun, 35(1), 213-221.

509 Suja, MS, Mahadevan, A, Sundaram, C, Mani, J, Sagar, BC, Hemachudha, T,
510 Wacharapluesadee, S, Madhusudana, SN, Shankar, SK (2004). Rabies encephalitis
511 following fox bite--histological and immunohistochemical evaluation of lesions
512 caused by virus. Clin Neuropathol, 23, 271-6.

513 Takayama-Ito, M, Inoue, K, Shoji, Y, Inoue, S, Iijima, T, Sakai, T, Kurane, I, Morimoto, K
514 (2006). A highly attenuated rabies virus HEP-Flury strain reverts to virulent by single
515 amino acid substitution to arginine at position 333 in glycoprotein. Virus Res, 119,
516 208-15.

517 Wang, ZW, Sarmiento, L, Wang, Y, Li, X, Dhingra, V, Tsegai, T, Jiang, B, Fu, ZF (2005).
518 Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate
519 immune responses in the central nervous system. J Virol, 79(19), 12554-12565.

520 Wiktor, TJ, Doherty, PC, Koprowski, H (1977). Suppression of cell-mediated immunity by
521 street rabies virus. *J Exp Med*, 145, 1617-1622.

522 Wilde, H (2007). Failures of post exposure prophylaxis. *Vaccine*, 25, 7605-7609.

523 Willoughby, RE, Tieves, KS, Hoffman, GM, Ghanayem, NS, Amelie-Lefond, CM, Schwabe,
524 MJ, Chusid, MJ, Rupprecht, CE (2005). Brief report: survival after treatment of rabies
525 with induction of coma. *N Engl J Med*, 352, 2508-2514.

526

527

528

529

530 Table 1. Different strains of RV used for infection.

RV Strains	Species of origin	Passage in the laboratory	Amounts of virus in the inoculum (f.f.u) ^a	References
CVS-F3 (challenge virus standard, escape mutant)	Dog	Cell culture	1×10^5	Dietzschold et al., 1983
ERA (Evelyn Rokitnicki Abelseth)	Dog	Cell culture	1×10^5	Abelseth, 1964
PM (Pittman Moore)	Dog	Cell culture	1×10^5	Rupprecht et al., 1992
HEP (high egg passage – flurry)	Dog	Cell culture	1×10^5	Takayama-Ito et al., 2006
SHBRV (silver haired bat-associated rabies virus)	Bat	Neonatal mouse brain	1×10^4	Dietzschold et al., 2000
DRV-4 (dog rabies virus)	Dog	Neonatal mouse brain	1×10^3	Dietzschold et al., 2000
Thai-DRV (Thai- dog rabies virus)	Dog	Neonatal mouse brain	1×10^5	Dietzschold et al., 2000
CVS-N2c (challenge virus standard)	Dog	Neonatal mouse brain ^b	1×10^5	Morimoto et al., 1999
CosRV (Coyote rabies virus)	Coyote	Neonatal mouse brain	1×10^4	Dietzschold et al., 2000
Skunk RV	Skunk	Neonatal mouse brain	1×10^4	Rupprecht et al., 1987

531

532 ^a The number of foci developed in 20 hours of *in-vitro* cultured monolayer of baby hamster
533 kidney (BHK) cells was counted as a measure of live virus particles in the inoculum.

534 ^b CVS-N2c was cloned in cell culture from parental CVS-24 strain, and then continued to
535 passage in neonatal mouse brain.

536

537

538

Table 2. Survival of mice following infection with different RV strains ^a.

Virus Strains	129/SvEv			PLSJL		
	Mortality ^b	Clinical signs	% Survival	Mortality	Clinical signs	% Survival
CVS-F3	0/20	Piloerection, weight loss	100	0/10	None	100
ERA	1/15	Piloerection, weight loss, hunched back, ataxia ^c	93	0/20		100
PM	0/15		100	0/10		100
DRV-4	10/10		0	0/10		100
SHBRV	20/20		Piloerection, weight loss, sudden onsets of severe agitation, vellication, ataxia, apnea	0	12/20	Dying: piloerection, weight loss, hunched back, apnea, vellication
Thai-DRV	15/15	0		15/17	Surviving: no clinical sign	11
CVS-N2c	20/20	0		18/20		10
CosRV	10/10	Dying: weight loss, ataxia, piloerection Surviving: none	0	1/20	Dying: piloerection, weight loss, ataxia Surviving: none	95
Skunk RV	9/10		10	1/10		90
HEP	0/15	None	100	0/10	None	100

540

541 ^a Two strains of mice were infected with different RV strains as described in the Materials
542 and Methods and observed for clinical signs and mortality for a period of 30 days.

543 ^b Number of mice that died over total number of mice used to monitor survival following an
544 infection.

545 ^c Clinical signs in 129/SvEv mice infected with ERA and PM begin to show 8-10 days post
546 infection and stay for 8-10 more days. Mice infected with DRV-4 show similar signs but die
547 within 3-4 days of the first appearance of clinical rabies.

548 **FIGURE LEGENDS**

549 **Figure 1. Detection of nucleoprotein message in the CNS of mice infected with different**
550 **RV strains.** RV nucleoprotein mRNA expression was detected in the CNS tissues (cerebral
551 cortex and cerebellum) of mice infected with different RV strains 8 days previously, by RT-
552 PCR as described in Materials and Methods. Results of 4 randomly chosen mice (numbered 1,
553 2, 3, 4) from each group of 10 mice are shown.

554

555 **Figure 2. Survival of mice following infection with different strains of RV.** Groups of 10
556 129/SvEv mice were infected with various RV strains listed in Table 1, via intra dermal
557 injection as described in Materials and Methods. Mice were monitored for morbidity and
558 mortality for 30 days. First 20 days observation is shown in the graph, there were no more
559 deaths in any of the groups between 20 to 30 days post infection.

560

561 **Figure 3. Innate immune response in the cerebellar tissues following infection with**
562 **different RV strains.** Mice were infected with different RV strains as described in Materials
563 and Methods. Eight days after infection, cerebellar tissues were collected and levels of
564 mRNAs specific for TNF- α and IL-6 genes were measured using QRT-PCR as described in
565 Materials and Methods. The levels of mRNA in each sample were normalized to the level of
566 L13 gene expression in those samples and are expressed as the fold-increase over the
567 expression levels detected in samples from uninfected control animals. Statistically significant
568 differences in gene expression between infected and uninfected mice were calculated using
569 Mann-Whitney test and are denoted by the symbol * ($p < 0.01$, $n=10$ in each group).

570

571 **Figure 4. Serum anti-RV antibody titers of the mice infected with different RV strains.**
572 Sera were collected from the uninfected and infected mice (n=10 per group) described in the
573 legend of Fig 3 and the amounts of RV-specific IgG molecules were measured using ELISA
574 as described in Materials and Methods. Antibody titer in the Y-axis is the inverse of the
575 dilution of a serum sample corresponding to the half of the maximum absorbance detected in
576 that sample. Statistically significant (*t*-test comparison with non-immune sera) levels of RV-
577 specific antibody titers are seen in the sera of all infected mice.

578

579 **Figure 5. Accumulation of immune cells in the cerebellar tissues following infection with**
580 **different RV strains.** Levels of mRNAs specific for CD4, κ -light chain (κ -LC) and CD19
581 genes were quantified using QRT-PCR in the total RNA isolated from the cerebellum of
582 uninfected and infected mice described in the legend of Fig 3 and normalized to L13 gene
583 expression in those samples as described in Materials and Methods. Levels of gene expression
584 are represented as the fold-increase in mRNA copy numbers over normalized copies in
585 samples from uninfected control animals as described in Materials and Methods. Statistically
586 significant differences in gene expression between infected and uninfected mice were
587 calculated using Mann-Whitney test and are denoted by the symbol ** $p < 0.01$ (n=10).

588

589 **Figure 6. BBB permeability changes in the cerebellum of the mice infected with different**
590 **RV strains.** BBB permeability was assessed by measuring the leakage of Na-fluorescein from
591 the circulation into the cerebellum 8 days after RV infection and are expressed as the fold-
592 increase in Na-fluorescein uptake by the CNS tissues of RV infected mice over that of
593 uninfected mice, as described in Materials and Methods. The dotted line represents the BBB

594 permeability in uninfected mice. Statistical significance of the differences in permeability
595 between infected and uninfected mice was calculated using Mann-Whitney test and are
596 denoted by the symbol ** $p < 0.01$, *** $p < 0.001$ (n=10).

597

598 **Figure 7. Nucleoprotein message levels in the cerebellar tissues of 129/SvEv and PLSJL**
599 **mice infected with CosRV and CVS-N2c RV strains.** Eight days post infection QRT-PCR
600 was used to quantify the levels of mRNAs specific for RV-nucleoprotein in total RNA
601 isolated from the cerebellar tissues of mice infected with CosRV and CVS-N2c RV strains
602 (n=5 per group). Levels normalized to L13 gene expression in the samples, as described in
603 Materials and Methods, are presented. Significantly higher levels of nucleoprotein mRNA in
604 CVS-N2c by comparison with CosRV infected mice are denoted by * ($p < 0.05$, *t*-test).
605 Significantly lower levels of nucleoprotein mRNA in PLSJL mice by comparison with
606 129/SvEv mice are denoted by # ($p < 0.05$, *t*-test).


607

608

609

610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632

FIGURE 1.



633

634 **FIGURE 2.**

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650


651

652

653

654

655



656

657 **FIGURE 3.**

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673


674

675

676


677

678



679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701

FIGURE 4.



702

703 **FIGURE 5.**

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719


720

721

722

723

724



725

726 **FIGURE 6.**

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742


743

744

745

746

747



748

749 **FIGURE 7.**

750

751

752

753

754

755

756

757

758

759

760

